Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Debate 28A Fertility-sparing Surgery in Early-stage Endometrial Cancer is Safe and Does not Compromise Oncological Outcome
- Debate 28B Fertility-sparing Treatment for Early-stage Endometrial Cancer is Safe and Does Not Compromise Oncological Outcome
- Debate 29A Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 29B Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 30A Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 30B Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 31A What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 31B What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 32A How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 32B How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 33A What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 33B What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 34A Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 34B Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 35A Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 35B Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 36A Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 36B Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 37A Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 37B Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 38A What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 38B What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 39A What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 39B What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 40A Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 40B Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 41A Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Debate 41B Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Debate 30A - Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
Yes
from Section IV - Endometrial Cancer
Published online by Cambridge University Press: 20 July 2023
By
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Debate 28A Fertility-sparing Surgery in Early-stage Endometrial Cancer is Safe and Does not Compromise Oncological Outcome
- Debate 28B Fertility-sparing Treatment for Early-stage Endometrial Cancer is Safe and Does Not Compromise Oncological Outcome
- Debate 29A Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 29B Sentinel Lymph Node Mapping Should be the Standard for Staging Patients with High-grade Endometrial Cancers
- Debate 30A Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 30B Molecular Profiling Should be Done to Guide the Management of Endometrial Cancer?
- Debate 31A What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 31B What is the Best Adjuvant Therapy for Management of Stage III Endometrial Cancer?
- Debate 32A How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 32B How Should Stage IA Serous Papillary Endometrial Cancer Confined to a Polyp or the Endometrial Lining be Managed?
- Debate 33A What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 33B What is the Optimal Sequence of Therapy for Patients with Stage IIIC Endometrial Carcinoma Treated with Multimodal Therapy?
- Debate 34A Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 34B Should an Attempt at Debulking Grossly Metastatic Endometrial Cancer be Undertaken?
- Debate 35A Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 35B Should Secondary Cytoreduction be Performed for Recurrent Endometrial Cancer?
- Debate 36A Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 36B Is Hormonal Therapy the Best Therapy for Chemo-resistant Endometrial Cancer?
- Debate 37A Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 37B Is there a Role for Using Immunotherapy in Endometrial Cancer?
- Debate 38A What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 38B What is the Best Chemotherapy Regimen for Uterine Carcinosarcoma?
- Debate 39A What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 39B What is the Best Management for Premenopausal Women with Early-stage Uterine Leiomyosarcoma Status Post Hysterectomy for Presumed Uterine Leiomyomas?
- Debate 40A Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 40B Should Primary Debulking Surgery be Performed for Metastatic Leiomyosarcoma?
- Debate 41A Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Debate 41B Should Secondary Cytoreductive Surgery be Offered to all Patients that are Surgical Candidates with Optimally Resectable Recurrent Uterine Leiomyosarcoma?
- Section V Cervical Cancer
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Summary
Both the National Comprehensive Cancer Network (NCCN) and the Society for Gynecologic Oncology (SGO) support the use of sentinel lymph node biopsy (SLNB) in the staging of apparent uterine-confined endometrial cancer. However, these recommendations are largely informed by retrospective and limited prospective studies performed in women with low-grade endometrial cancer (LGEC). The use of SLNB in women with high-grade endometrial cancers (HGEC), which are more biologically aggressive, have a higher risk of lymphatic spread, and poorer survival outcomes than those with LGEC, remains a matter of debate.
Information
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 179 - 181Publisher: Cambridge University PressPrint publication year: 2023
References
de Boer, SM, et al; for PORTEC Study Group. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol 2018;29(2):424–430. https://doi.org/10.1093/annonc/mdx753CrossRefGoogle Scholar
Cancer Genome Atlas Research Network, Kandoth, C, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67–73. https://doi.org/10.1038/nature12113. Erratum in: Nature 2013;500(7461):242.Google ScholarPubMed
DeLair, DF, et al. The genetic landscape of endometrial clear cell carcinomas. J Pathol 2017;243(2):230–241. https://doi.org/10.1002/path.4947CrossRefGoogle ScholarPubMed
Stelloo, E, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer: combined analysis of the PORTEC cohorts. Clin Cancer Res 2016;22(16):4215–4224. https://doi.org/10.1158/1078-0432.CCR-15-2878CrossRefGoogle ScholarPubMed
Salvador, MU, et al. Comprehensive paired tumor/germline testing for lynch syndrome: bringing resolution to the diagnostic process. J Clin Oncol 2019;37(8):647–657. https://doi.org/10.1200/JCO.18.00696CrossRefGoogle Scholar
Accessibility standard: Unknown
Accessibility compliance for the PDF of this book is currently unknown
and may be updated in the future.